Kintor’s COVID-19 treatment reduces mortality by 92%
pharmafile | March 12, 2021 | News story | Medical Communications | Brazil, Brazil variant, COVID-19, Kintor, covid-19 treatment
Kintor Pharmaceutical’s Proxalutamide treatment has been proven to reduce risk of mortality from COVID-19 by 92%, in a clinical trial conducted on patients in Brazil.
The Phase III study, which administered 294 patients with Proxalutamide and 296 patients with a placebo, measured the efficacy of the drug relative to standard care. According to the results on day 14, the mortality in the Proxalutamide arm was 3.7%, compared to 47.6% in the control arm, demonstrating the reduced mortality risk of 92%.
On top of this, the median hospital length for those given Proxalutamide was 5 days, compared to 14 for those on the placebo, meaning Kintor’s treatment also shortened hospital stay by 9 days on average.
The trial mainly involved patients infected with the new strain of the virus that developed in Brazil, amid fears that this variant may be more difficult to treat.
Proxalutamide is a nonsteroidal antiandrogen – a selective high-affinity silentantagonist of the androgen receptor. It is in development for the potential treatment of prostate cancer and breast cancer, as well as COVID-19.
Dr Tong Youzhi, Founder, Chairman, and CEO of Kintor, said: “This trial for treatment of hospitalised COVID-19 patients was conducted in 12 sites in the Brazilian state of Amazonas, where the pandemic has been devastating. Most of the newly test-positive patients in Amazonas have been infected by the new P.1 variant, which is more contagious and has led to a higher mortality rate.
“We are delighted to see that Proxalutamide could significantly reduce the mortality rate, shorten the length of hospital stay, reduce the number of new mechanical ventilations, and increase the percentage of discharge from hospital, thus alleviating shortages of public health resources in Amazonas. Based on the positive results of this Phase III trial, we expect Proxalutamide could become an important tool in the global fight against COVID-19.”
Jack Goddard
Related Content
COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …
Mental health medicine use in England reaches record high, NHSBSA report reveals
According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions …
FDA approves Moderna’s Spikevax for children at increased risk of COVID-19
Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, …
